Cost-effectiveness analysis of the subcutaneous use of Lanadelumab for prevention of recurrent attacks of hereditary angioedema in the healthcare of the Republic of Kazakhstan

Abstract

Currently, the process of collecting statistical data on the prevalence of hereditary angioedema (HAE) in the world, as well as the formation of a database of patients with this pathology, separately for each country, are ongoing.
In this study, we evaluated the cost-effectiveness of the subcutaneous use of Lanadelumab (Takhzyro) for prevention of recurrent HAE attacks in adults and children over 12 years of age, compared with subcutaneous administration of a C1-esterase inhibitor in the healthcare of the Republic of Kazakhstan.
The results of the base case of the cost-effectiveness model showed that the subcutaneous use of Lanadelumab for prevention of recurrent attacks of hereditary angioedema, compared with the subcutaneous administration of a C1-esterase inhibitor is dominant, that is, preferable, due to an increase in QALY (0.515) and significant cost savings (up to 3.5 billion tenge on average per patient life cycle). The model calculated an increase to an additional 4.1 QALYs and a cost-effectiveness of 61.6 million tenge per QALY, demonstrating the cost-effectiveness of the subcutaneous Lanadelumab versus best supportive therapy.